A new therapeutic use of the botulinum neurotoxin serotype a

Abstract

A new therapeutic use of botulinum neurotoxin serotype A (Bont/A) is described, therapeutic treatment of paralysis caused by spinal cord injury.

1 . A botulinum neurotoxin serotype A for use in the therapeutic treatment of paralysis caused by spinal cord injury. 
     
     
         2 . The botulinum neurotoxin serotype A for use according to  claim 1 , which is selected from the group consisting of botulinum neurotoxin serotype A1 and botulinum neurotoxin serotype A2. 
     
     
         3 . The botulinum neurotoxin serotype A for use according to  claim 1 , wherein the paralysis is paraplegia or tetraplegia. 
     
     
         4 . The botulinum neurotoxin serotype A for use according to  claim 1 , wherein the therapeutic treatment comprises intrathecal administration of botulinum neurotoxin serotype A. 
     
     
         5 . The botulinum neurotoxin serotype A for use according to  claim 4 , wherein the intrathecal administration is carried out by injection in the vertebral area immediately caudal to the area affected by said spinal cord injury. 
     
     
         6 . The botulinum neurotoxin serotype A for use according to  claim 1 , wherein the therapeutic treatment comprises administering to a patient a pharmaceutically effective amount of the botulinum neurotoxin serotype A, in which the patient is a human being. 
     
     
         7 . The botulinum neurotoxin serotype A for use according to  claim 1 , wherein the pharmaceutically effective amount of botulinum neurotoxin serotype A is in the range of from 75 units to 360 units. 
     
     
         8 . A pharmaceutical composition comprising a pharmaceutically effective amount of botulinum neurotoxin serotype A and at least one pharmaceutically acceptable vehicle, excipient or diluent, for use in the therapeutic treatment of paralysis caused by spinal cord injury. 
     
     
         9 . The pharmaceutical composition for use according to  claim 8 , wherein the botulinum neurotoxin serotype A is selected from the group consisting of botulinum neurotoxin serotype A1 and botulinum neurotoxin serotype A2. 
     
     
         10 . The pharmaceutical composition for use according to  claim 8 , wherein the paralysis is paraplegia or tetraplegia. 
     
     
         11 . The pharmaceutical composition for use according to  claim 8 , wherein the pharmaceutically effective amount of botulinum neurotoxin serotype A is in the range of from 75 units to 360 units. 
     
     
         12 . The pharmaceutical composition for use according to  claim 8 , which is formulated for administration by injection. 
     
     
         13 . The pharmaceutical composition for use according to  claim 12 , which is formulated for administration by intrathecal injection.